bih.button.backtotop.text
BROWSE BY TEST NAME
%
1
2
3
5
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Clear
 
Test Code:
090-71-0006

Order Name:
HIV-1 Drug Resistant Genotype (Protease & RT & IN) **

 
Useful For:
To manage HIV-1 treatment.
This test is intended to be used to monitor known HIV-positive infections. It is not intended for primary detection of HIV infections.
Specimens should contain a minimum HIV viral load of 1000 copies/ml. Testing may be cancelled if the specimen supplied is inadequate.
 
Methodology:
Amplify HIV-1 protease, reverse transcriptase and integrase region, then genotyping by direct sequencing method. Compare the sequence with Stanford database.
 
Test List In Profile:
PI (Protease Inhibitor)
RTI (Reverse transcriptase inhibitor)
IN (Integrase inhibitor)
 
AliasesName:
HIV-1 drug resistance (PI+RTI+INI)
Human Immunodeficiency Virus Genotype
 
 
 
Test Code:
090-71-0006

Order Name:
HIV-1 Drug Resistant Genotype (Protease & RT & IN) **

 
Collection Specimen Or Container:
Blood/ K3 EDTA (Lavender Top) 3 mL, 2 tubes
 
Specimen Testing Type:
Plasma EDTA, minimum volume 2 mL - Separate plasma within 6 hours of collection.
 
Sub Mission Container:
Plastic tube
 
Specimen Stabillity:
Specimen Type Temperature Time
Plasma, EDTA Refrigerated, 2oC to 8oC 5 days
Frozen 35 days
 
 
 
Test Code:
090-71-0006

Order Name:
HIV-1 Drug Resistant Genotype (Protease & RT & IN) **

 
Method detail:
Amplify HIV-1 protease, reverse transcriptase and integrase region, then genotyping by direct sequencing method. Compare the sequence with Stanford database.
 
Schedule:
N/A **Sent Out to N Health
 
Turnaround Time:
14 days
 
Performing Location:
N Health
Referral Lab Services, Laboratory Department 14160-2
 
 
 
Test Code:
090-71-0006

Order Name:
HIV-1 Drug Resistant Genotype (Protease & RT & IN) **

 
 
Clinical Information:
HIV-1 is an RNA virus that infects cells and is then converted to complementary DNA (cDNA) by the action of the viral reverse transcriptase (RT). RT has little proofreading capacity and therefore incorporates errors in the proviral DNA. These errors are transcribed into infectious viral particles when the proviral DNA is transcribed into RNA. Similarly, the enzyme protease (PR) catalyzes a polyprotein to produce peptides necessary for active viral replication. Although HAART (combinations of nucleoside analogs, nonnucleoside agents, protease inhibitors and/or integrase strand transfer inhibitors) may be effective in reducing viral load, genotypic mutations arising in drug-targeted HIV loci due to selective pressure from antiviral therapy can result in antiviral resistance that may compromise such therapy.
 
Reference Value:
N/A
 
Interpretation:
Detectable HIV-1 genotypic mutations conferring resistance to an antiviral drug are reported as amino acid codon changes (eg, N155H), along with associated resistance interpretations for the current FDA-approved integrase strand transfer inhibitors (dolutegravir, elvitegravir, and raltegravir). Interpretation for resistance to bictegravir is not available at present.
 
Clinical Reference:
  1. N Health Laboratory Catalog 2017
  2. www.mayomedicallaboratories.com (Retrieved: 24 Jan 2019)